Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
FOXO Technologies ( (FOXO) ) has shared an update.
On August 13, 2025, FOXO Technologies Inc. announced that its Class A common stock would be delisted from the NYSE American due to low selling prices, as confirmed by a letter from NYSE on August 12, 2025. The company has arranged for its stock to be traded on the OTC market starting August 13, 2025, and remains committed to its business strategy and growth plans despite the delisting.
Spark’s Take on FOXO Stock
According to Spark, TipRanks’ AI Analyst, FOXO is a Underperform.
FOXO Technologies receives a low overall stock score primarily due to significant financial challenges, including continuous net losses, high debt, and negative cash flows. The technical analysis also suggests bearish momentum. Although valuation metrics are poor, recent corporate actions, such as acquisitions and restructuring, provide some hope for future improvement. However, these are not sufficient to outweigh the current financial and operational challenges facing the company.
To see Spark’s full report on FOXO stock, click here.
More about FOXO Technologies
FOXO Technologies Inc. operates in the healthcare and biotechnology industries, owning subsidiaries such as Rennova Community Health, Inc., which manages a critical access hospital in East Tennessee, Myrtle Recovery Centers, Inc., a behavioral health facility, and FOXO Labs, Inc., a biotechnology company focused on improving human health and lifespan through advanced technology.
Average Trading Volume: 5,941,883
Technical Sentiment Signal: Sell
Current Market Cap: $933.3K
For detailed information about FOXO stock, go to TipRanks’ Stock Analysis page.